Joel Wayment: Rethinking Waste in the Cold Chain

Key Takeaways

• Reusable cold‑chain containers cut waste and lower shipping costs
• One‑time gel packs can be repurposed for community food programs
• Cardinal Health pilots reusable packaging models ahead of Asembia AXS26
• Switching to reusable reduces disposal fees for manufacturers
• Scalable reuse improves sustainability metrics across pharma supply chains

Pulse Analysis

The pharmaceutical cold chain has long been a sustainability blind spot, with single‑use gel packs and insulated boxes generating tons of waste each year. Although the industry has embraced recyclable films and cardboard, the core thermal protection components remain disposable, driving both landfill volume and hidden costs. As regulators and investors press for greener operations, companies are forced to examine the full lifecycle of their temperature‑controlled shipments, not just the surface‑level recyclability.

Cardinal Health’s recent push toward reusable containers reflects a broader shift toward circular logistics. By designing insulated containers that can be returned, cleaned, and redeployed, manufacturers can cut packaging spend by up to 20 percent while slashing waste disposal fees. Pilot programs at major pharma clients have shown that a closed‑loop system reduces carbon emissions per shipment and improves inventory visibility through tracking tags. The cost savings stem from fewer purchase orders for single‑use items and lower handling fees, making the model financially attractive even before accounting for ESG incentives.

Beyond cost and carbon benefits, repurposing non‑reusable items opens new community partnerships. Gel packs that can no longer serve a shipment are being donated to food‑delivery services and school lunch programs, extending their useful life and reinforcing corporate social responsibility. As the industry scales these initiatives, standards bodies may codify reusable packaging requirements, accelerating adoption. Ultimately, the move from disposable to reusable cold‑chain assets promises a more resilient, sustainable, and socially responsible pharmaceutical supply chain.